Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration

Despite the success of anti-vascular endothelial growth factors (anti-VEGFs), currently, there is a need for highly effective compounds that can alleviate the burden of managing neovascular age-related macular degeneration (nAMD). To review the milestones in the molecular and clinical development of...

Full description

Bibliographic Details

Published in:	Ophthalmologica (Basel) Vol. 244; no. 2; p. 93
Main Authors:	Tadayoni, Ramin, Sararols, Laura, Weissgerber, Georges, Verma, Rohini, Clemens, Andreas, Holz, Frank G
Format:	Journal Article
Language:	English
Published:	Switzerland 01.05.2021
Subjects:	Neovascular age-related macular degeneration (AMD) Anti-VEGF Brolucizumab Single-chain antibody fragment
ISSN:	1423-0267, 1423-0267
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!